Latest Period
Q4 2025
Security Snapshot
REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) Institutional Ownership
CUSIP: 76152G100
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
44
Shares (Excl. Options)
11,148,640
Price
$0.28
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- RVPH on Nasdaq
- Shares outstanding
- 12,863,707
- Price per share
- $0.18
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 11,148,640
- Total reported value
- $3,114,479
- % of total 13F portfolios
- 0%
- Share change
- +1,662,587
- Value change
- +$129,897
- Number of holders
- 44
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share is tracked under CUSIP 76152G100.
- 44 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 44 to 1 between Q4 2025 and Q1 2026.
- Reported value moved from $3,114,479 to $714.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 44 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 76152G100?
CUSIP 76152G100 identifies RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 76152G100:
Significant Owners of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 9.9% | $3,120,000 | 8,000,000 | HIGHBRIDGE CAPITAL MANAGEMENT, LLC | 30 Jun 2025 | |||
| Bhat Laxminarayan | 3.8% | -28% | $1,877,246 | +$34,930 | 3,680,874 | +1.9% | Bhat Laxminarayan | 22 Sep 2025 |
| 683 Capital Management, LLC | 3% | -47% | $1,257,300 | -$699,300 | 3,492,500 | -36% | 683 CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
| TANG CAPITAL MANAGEMENT LLC | 4.8% | -38% | $1,325,990 | -$199,028 | 3,399,975 | -13% | TANG CAPITAL MANAGEMENT, LLC | 30 Jun 2025 |
| Schonfeld Strategic Advisors LLC | 2.8% | $1,157,125 | 1,314,915 | Schonfeld Strategic Advisors LLC | 31 Dec 2024 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 6.2% | +113% | $174,669 | -$542,018 | 793,952 | -76% | Integrated Core Strategies (US) LLC | 23 Mar 2026 |
| UBS Group AG | 5.8% | $133,178 | 746,095 | UBS Group AG | 31 Mar 2026 | |||
| CVI Investments, Inc. | 5.2% | +6% | $146,667 | -$639,086 | 666,667 | -81% | CVI Investments, Inc. | 18 Mar 2026 |
| SAXENA PARAG | 2.8% | -48% | $79,922 | -$1,299,040 | 363,280 | -94% | Parag Saxena | 20 Mar 2026 |
As of 31 Dec 2025, 44 institutional investors reported holding 11,148,640 shares of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH). This represents 87% of the company’s total 12,863,707 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 25% | 3,197,581 | +66% | 0% | $892,125 |
| MILLENNIUM MANAGEMENT LLC | 18% | 2,263,470 | +32% | 0% | $631,508 |
| GEODE CAPITAL MANAGEMENT, LLC | 8.2% | 1,048,954 | +88% | 0% | $292,683 |
| JANE STREET GROUP, LLC | 7% | 894,749 | +292% | 0% | $249,636 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 5.3% | 682,053 | +30% | 0% | $190,293 |
| CITADEL ADVISORS LLC | 4.3% | 554,630 | 0% | $154,742 | |
| STATE STREET CORP | 3% | 383,200 | +202% | 0% | $106,913 |
| BlackRock, Inc. | 2.9% | 371,661 | +546% | 0% | $103,693 |
| UBS Group AG | 2.8% | 359,455 | 0% | $100,288 | |
| MORGAN STANLEY | 2.6% | 337,315 | +8087% | 0% | $94,110 |
| NORTHERN TRUST CORP | 1.6% | 209,373 | +193% | 0% | $58,415 |
| XTX Topco Ltd | 1.3% | 164,291 | +64% | 0% | $45,837 |
| Lido Advisors, LLC | 0.74% | 94,739 | -4.9% | 0% | $31,133 |
| GROUP ONE TRADING LLC | 0.48% | 62,365 | 0% | $17,400 | |
| Focus Partners Wealth | 0.41% | 53,000 | 0% | 0% | $14,787 |
| Corient Private Wealth LLC | 0.3% | 38,000 | 0% | $10,602 | |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.28% | 36,261 | +79% | 0% | $10,120 |
| CUTLER INVESTMENT COUNSEL LLC | 0.26% | 33,500 | 0% | $9,347 | |
| BECKER CAPITAL MANAGEMENT INC | 0.25% | 32,580 | 0% | $9,090 | |
| Creative Planning | 0.25% | 32,107 | 0% | 0% | $8,958 |
| HRT FINANCIAL LP | 0.24% | 31,112 | 0% | $8,000 | |
| TWO SIGMA SECURITIES, LLC | 0.24% | 30,727 | 0% | $8,573 | |
| AQR CAPITAL MANAGEMENT LLC | 0.22% | 28,001 | 0% | 0% | $7,812 |
| Cetera Investment Advisers | 0.19% | 23,800 | -60% | 0% | $6,641 |
| Kestra Advisory Services, LLC | 0.16% | 20,000 | 0% | $5,580 |
Institutional Holders of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (RVPH) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,000 | $714 | -$136,239 | $0.18 | 1 |
| 2025 Q4 | 11,148,640 | $3,114,479 | +$129,897 | $0.28 | 44 |
| 2025 Q3 | 9,477,953 | $3,493,458 | -$2,523,110 | $0.37 | 40 |
| 2025 Q2 | 14,276,867 | $5,439,564 | +$2,030,904 | $0.38 | 44 |
| 2025 Q1 | 7,316,794 | $6,939,218 | -$2,147,972 | $0.95 | 47 |
| 2024 Q4 | 7,732,309 | $14,008,817 | -$4,024,379 | $1.81 | 42 |
| 2024 Q3 | 9,947,227 | $14,936,260 | +$4,666,858 | $1.44 | 33 |
| 2024 Q2 | 6,849,687 | $8,748,871 | +$1,342,404 | $1.28 | 30 |
| 2024 Q1 | 5,573,837 | $21,010,997 | -$1,861,302 | $3.78 | 28 |
| 2023 Q4 | 5,266,256 | $27,119,158 | +$12,592,563 | $5.15 | 35 |
| 2023 Q3 | 2,663,385 | $13,004,016 | -$556,556 | $4.88 | 24 |
| 2023 Q2 | 2,636,201 | $15,447,187 | +$8,416,328 | $5.86 | 22 |
| 2023 Q1 | 1,375,662 | $5,761,612 | +$298,180 | $4.19 | 22 |
| 2022 Q4 | 1,303,532 | $5,539,575 | +$1,730,868 | $4.25 | 23 |
| 2022 Q3 | 865,615 | $1,376,000 | -$905,812 | $1.59 | 15 |
| 2022 Q2 | 1,865,547 | $2,053,000 | -$115,802 | $1.10 | 9 |
| 2022 Q1 | 1,902,181 | $4,678,000 | -$2,054,792 | $2.46 | 14 |
| 2021 Q4 | 2,612,910 | $7,543,000 | -$15,645 | $2.89 | 11 |
| 2021 Q3 | 2,603,081 | $10,549,000 | -$229,537 | $4.06 | 11 |
| 2021 Q2 | 2,652,392 | $12,779,000 | +$9,606,649 | $4.86 | 11 |
| 2021 Q1 | 586,328 | $3,365,000 | +$1,292,854 | $5.74 | 7 |
| 2020 Q4 | 360,070 | $3,149,000 | +$3,149,000 | $8.77 | 3 |